Monthly Archives: June 2024

Class 3 Medicines Recall: GoResp Digihaler (Teva UK Ltd) Drug alert number: EL (24)A/23 Date issued: 18 June 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines recall for GoResp Digihaler (Teva UK Ltd). Company name: Teva UK Ltd Product name: GoResp Digihaler, PLGB 00289/2501 SNOMED Code: 42007211000001108 Batch Number [...]

The post MHRA Class 3 Medicines Recall: GoResp Digihaler (Teva UK Ltd) appeared first on Community Pharmacy England.

Pharmacy owners across the North East are invited to meet the Community Pharmacy England team to discuss the issues that matter to you. Chief Executive Janet Morrison and the team are heading to Newcastle on the evening of Wednesday 3rd July to talk directly to local pharmacy owners. Our regional roadshow will outline all of [...]

The post North East Pharmacy Owners: Book your place for our regional roadshow appeared first on Community Pharmacy England.

LPCs across Cheshire and Merseyside have been reviewing Pharmacy First data and have identified several referrals from GP practices where a pharmacy has rejected a referral where a Minor illness consultation could have been completed and claimed. The data also showed examples of where the rejection message showed that a consultation had taken place, but [...]

The post Pharmacy First: To reject or not to reject? appeared first on Community Pharmacy England.

The Centre for Pharmacy Postgraduate Education (CPPE) has launched a Common clinical conditions e-learning programme. This e-learning programme is designed to help update pharmacy professionals’ knowledge and skills to help with the management of common clinical conditions and minor ailments that may present themselves in community pharmacy. The programme contains practical tips and advice on [...]

The post Pharmacy First: CPPE launches Common clinical conditions e-learning appeared first on Community Pharmacy England.

Class 4 Medicines Defect Information: Oxcarbazepine Mylan 150 mg, 300mg, 600mg Film-Coated Tablets (Mylan) Drug alert number: EL (24)A/22 Date issued: 17 June 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Oxcarbazepine Mylan 150 mg, 300mg, 600mg Film-Coated Tablets (Mylan) Company name: Viatris UK Healthcare [...]

The post MHRA Class 4 Medicines Defect Information: Oxcarbazepine Mylan 150 mg, 300mg, 600mg Film-Coated Tablets (Mylan) appeared first on Community Pharmacy England.